



CANCER
HAS NO BORDERS
NEITHER DO WE



The BeiGene Story

A global biotechnology innovator focused on improving treatment outcomes and patient access.

BeiGene is a global biotechnology company co-founded in 2010 by **John Oyler**, an American entrepreneur, and **Dr. Xiaodong Wang**, world renowned biochemist and youngest ever U.S. Academy of Science member, to deliver cancer medicines more broadly and improve the lives of patients worldwide.

Our founders united to benefit patients with cancer – wherever they live – by building a unique operating model, founded on the belief that innovative, impactful and high-quality medicines can be made faster and more affordable around the world.

Today, we are more than **8,000** colleagues across **five** continents. We have built sustainable competitive advantages including predominantly fully integrated global clinical development, science-based commercial teams in China, the U.S., and Europe, a robust research pipeline, and state-of-the-art internal manufacturing capabilities. Our internally-developed BTK inhibitor, zanubrutinib, is approved in more than **40** countries and regions around the world.

Our mission is to build the first next-generation biotechnology company – one **that expands the highest quality therapies to more people around the world** – through courage, persistent innovation, and challenging the status quo.



Our Commitment to Patients

Cancer has no borders. Neither do we.

Our passion is partnership.

Our commitment to patients is resolute.

We strive every day to create high-quality, innovative medicines that are more accessible and affordable to more people. We want to ensure patients can access them; it's not enough for innovative drugs to simply exist.


We work with cancer communities in the U.S. and around the world to learn from and provide support to patients, caregivers, and families to raise awareness and improve lives.

- **We communicate** honestly, transparently, and accurately.
- **We listen** with empathy to learn from patients/caregivers and connect with them.
- **We respect** the healthcare provider/patient relationship.
- **We empower** patients through education and resources to manage their disease.
- **We respect** diversity and promote inclusion among all people impacted by cancer.
- **We support** initiatives and programs that help patients live fuller, more engaged lives.
- **We provide** opportunities for our employees to engage with cancer communities.



Cancer is **Relentless.** Our **Scientists** are too.

We are advancing an innovative, high-value product candidate portfolio in the service of patients worldwide, as we are committed to improving global access and affordability.



100+ clinical trials initiated to date in **45** countries and regions

Our world-class research and development engine has:

- One of the **largest** oncology research teams and portfolios
- **11** internally-discovered molecules to the clinic in the first **10 years**
- **3** internally discovered approved medicines
- **~50** molecules at commercial or clinical stage
- **50+** preclinical programs ongoing, **50%** of which are potentially first-in-class
- **30+** Phase **3** or potentially registration-enabling trials

Our Clinical Pipeline from Internal Discovery

We are passionate about applying cutting-edge science to the development of life-changing therapies.

BeiGene's current pipeline, including early-stage clinical development assets, is available at www.BeiGene.com.

Safety and efficacy have not been established for investigational products and uses.

Late-Stage Clinical Development	
Zanubrutinib (BTK)	<ul style="list-style-type: none"> • Second generation small molecule inhibitor of Bruton's tyrosine kinase • Currently being investigated as a monotherapy and in combination with other therapies in multiple hematologic malignancies
Tislelizumab (PD-1)	<ul style="list-style-type: none"> • Humanized IgG4 anti-PD-1 monoclonal antibody • Currently being investigated as a monotherapy and in combination with other therapies in multiple solid tumors and hematologic malignancies
Pamiparib (PARP)	<ul style="list-style-type: none"> • Small molecule inhibitor of PARP1 and PARP2 • Currently being investigated as a monotherapy and in combination with other therapies in multiple solid tumors
Ociperlimab (TIGIT)	<ul style="list-style-type: none"> • Investigational TIGIT monoclonal antibody • Currently being investigated in combination with tislelizumab in solid tumors
Early-Stage Clinical Development	
BGB-A445 (OX40)	<ul style="list-style-type: none"> • Investigational OX40 agonist antibody • Currently being investigated as a monotherapy and in combination with tislelizumab in solid tumors
BGB-A425 (TIM-3)	<ul style="list-style-type: none"> • Investigational humanized IgG1-variant monoclonal antibody against TIM-3 • Currently being investigated in combination with tislelizumab in solid tumors
BGB-11417 (BCL-2)	<ul style="list-style-type: none"> • Investigational small molecule Bcl-2 inhibitor • Currently being investigated as a monotherapy and in combination with zanubrutinib in hematologic malignancies
BGB-10188 (PI3-K δ)	<ul style="list-style-type: none"> • Investigational phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor • Currently being investigated as a monotherapy, in combination with zanubrutinib in hematologic malignancies, and in combination with tislelizumab in solid tumors
Lifirafenib (BRAF Dimer)	<ul style="list-style-type: none"> • Investigational small molecule inhibitor of the RAF protein • Currently being investigated as a monotherapy and in combination with other therapies in solid tumors
BGB-15025 (HPK1)	<ul style="list-style-type: none"> • Investigational hematopoietic progenitor kinase 1 (HPK1) inhibitor • Currently being investigated as a monotherapy and in combination with tislelizumab in solid tumors
BGB-23339 (TYK2)	<ul style="list-style-type: none"> • Investigational tyrosine kinase 2 (TYK2) inhibitor • Currently being investigated as a monotherapy in inflammation and immunity

Partner of Choice

Global strategic oncology collaborations to expand access to important oncology medicines for patients around the globe.

We are committed to collaborating with academia, biotech and pharmaceutical companies around the world to jointly discover and develop innovative products that will bring meaningful treatments to patients.

Additional Collaborations



Amgen Collaboration:

- BeiGene is commercializing **three** Amgen oncology products in China — XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab).
- Amgen invested **\$2.8B** for a **20.5%** stake in BeiGene.



Novartis Collaborations:

- Novartis to co-develop and commercialize BeiGene's **Anti-PD-1 Antibody Tislelizumab** in North America, Japan, EU, and **6 other** European countries.
- Novartis has an option for BeiGene and Novartis to collaborate on the development, manufacturing and commercialization of BeiGene's investigational **TIGIT Inhibitor Ociperlimab** in North America, Japan, EU and **6 other** European countries.
- BeiGene to market and promote **five** Novartis approved and **nationally reimbursed** oncology products, including TAFINLAR® (dabrafenib), MEKINIST® (trametinib), VOTRIENT® (pazopanib), AFINITOR® (everolimus), ZYKADIA® (ceritinib), in designated regions of China referred to as Broad Markets.

Our Environmental, Social & Governance Commitment

At BeiGene, we are driven by the power of change.

We lead change by:

- Making **life-saving** medicines accessible to more patients around the world.
- **Challenging** the status quo and **pushing** the boundaries to make the impossible possible.
- **Removing** systemic injustices and inequities.
- Creating **boundless** opportunities for people to thrive.
- Having the transformative **ability** to shift paradigms.

At BeiGene, we believe that **Change Is The Cure**. Our ambition is to be a leading corporate citizen, acting with courage, creativity, and discipline to ensure we are meeting the diverse needs of our stakeholders – **from patients and colleagues to investors and communities, as well as the environment.**

BeiGene formalized its Environmental, Social, and Governance (**ESG**) function and defined the company's new **global ESG strategy and framework, Change Is The Cure**, in 2021.






BeiGene

Cancer has no borders. Neither do we.

 [BeiGene.com](https://www.BeiGene.com)

 [@BeiGeneGlobal](https://twitter.com/BeiGeneGlobal)

 info@BeiGene.com

 888-123-4455

 [LinkedIn.com/Company/BeiGene/](https://www.linkedin.com/company/BeiGene/)